SMAD2 and neoplasm: In an in vitro cell model or in vivo tumor tissues, dipyridamole treatment resulted in a decline in the levels of HMGB1, RAGE, β-catenin, Runx2, YAP1, phosphorylated Smad2/3, and cyclin D1, but not TLR2 and TLR4.